Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy

Cezary Wojcik, Michelle L. Schymik, Eric G. Cure

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Aims: The purpose of this study was to evaluate the effectiveness of a new, fixed, yet individualized dosing regimen of activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for warfarin reversal in the setting of a life-threatening bleeding in a secondary care center. Methods: In this report we present a retrospective chart review of 72 patients who received FEIBA and 69 patients who received fresh-frozen plasma (FFP) to reverse the effects of warfarin in a setting of a life-threatening bleeding. In the FEIBA cohort, patients received 500 units of FEIBA when the initial INR was

Original languageEnglish (US)
Pages (from-to)217-225
Number of pages9
JournalInternational Journal of Emergency Medicine
Volume2
Issue number4
DOIs
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Factor VIII
Warfarin
Secondary Care Centers
Hemorrhage
International Normalized Ratio
prothrombin complex concentrates

Keywords

  • Activated prothrombin complex concentrate
  • Coagulopathy
  • Factor VIII inhibitor bypassing activity (FEIBA)
  • Fresh-frozen plasma
  • International normalized ratio
  • Warfarin
  • Warfarin reversal

ASJC Scopus subject areas

  • Emergency Medicine

Cite this

Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. / Wojcik, Cezary; Schymik, Michelle L.; Cure, Eric G.

In: International Journal of Emergency Medicine, Vol. 2, No. 4, 12.2009, p. 217-225.

Research output: Contribution to journalArticle

@article{73f5b67511ae4cecb41371fdb6016feb,
title = "Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy",
abstract = "Aims: The purpose of this study was to evaluate the effectiveness of a new, fixed, yet individualized dosing regimen of activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for warfarin reversal in the setting of a life-threatening bleeding in a secondary care center. Methods: In this report we present a retrospective chart review of 72 patients who received FEIBA and 69 patients who received fresh-frozen plasma (FFP) to reverse the effects of warfarin in a setting of a life-threatening bleeding. In the FEIBA cohort, patients received 500 units of FEIBA when the initial INR was",
keywords = "Activated prothrombin complex concentrate, Coagulopathy, Factor VIII inhibitor bypassing activity (FEIBA), Fresh-frozen plasma, International normalized ratio, Warfarin, Warfarin reversal",
author = "Cezary Wojcik and Schymik, {Michelle L.} and Cure, {Eric G.}",
year = "2009",
month = "12",
doi = "10.1007/s12245-009-0125-8",
language = "English (US)",
volume = "2",
pages = "217--225",
journal = "International Journal of Emergency Medicine",
issn = "1865-1372",
publisher = "Springer London",
number = "4",

}

TY - JOUR

T1 - Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy

AU - Wojcik, Cezary

AU - Schymik, Michelle L.

AU - Cure, Eric G.

PY - 2009/12

Y1 - 2009/12

N2 - Aims: The purpose of this study was to evaluate the effectiveness of a new, fixed, yet individualized dosing regimen of activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for warfarin reversal in the setting of a life-threatening bleeding in a secondary care center. Methods: In this report we present a retrospective chart review of 72 patients who received FEIBA and 69 patients who received fresh-frozen plasma (FFP) to reverse the effects of warfarin in a setting of a life-threatening bleeding. In the FEIBA cohort, patients received 500 units of FEIBA when the initial INR was

AB - Aims: The purpose of this study was to evaluate the effectiveness of a new, fixed, yet individualized dosing regimen of activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for warfarin reversal in the setting of a life-threatening bleeding in a secondary care center. Methods: In this report we present a retrospective chart review of 72 patients who received FEIBA and 69 patients who received fresh-frozen plasma (FFP) to reverse the effects of warfarin in a setting of a life-threatening bleeding. In the FEIBA cohort, patients received 500 units of FEIBA when the initial INR was

KW - Activated prothrombin complex concentrate

KW - Coagulopathy

KW - Factor VIII inhibitor bypassing activity (FEIBA)

KW - Fresh-frozen plasma

KW - International normalized ratio

KW - Warfarin

KW - Warfarin reversal

UR - http://www.scopus.com/inward/record.url?scp=73549085173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73549085173&partnerID=8YFLogxK

U2 - 10.1007/s12245-009-0125-8

DO - 10.1007/s12245-009-0125-8

M3 - Article

C2 - 20436891

AN - SCOPUS:73549085173

VL - 2

SP - 217

EP - 225

JO - International Journal of Emergency Medicine

JF - International Journal of Emergency Medicine

SN - 1865-1372

IS - 4

ER -